| Literature DB >> 32567846 |
Christoph Federer1,2, Markus Kurpiers1,2, Andreas Bernkop-Schnürch2.
Abstract
Various properties of chitosan can be customized by thiolation for very specific needs in a wide range of application areas. Since the discovery of thiolated chitosans, many studies have proven their advantageous characteristics, such as adhesion to biological surfaces, adjustable cross-linking and swelling behavior, controllable drug release, permeation as well as cellular uptake enhancement, inhibition of efflux pumps and enzymes, complexation of metal ions, antioxidative properties, and radical scavenging activity. Simultaneously, these polymers remain biodegradable without increased toxicity. Within this Review, an overview about the different possibilities to covalently attach sulfhydryl ligands to the polymeric backbone of chitosan is given, and the resulting versatile physiochemical properties are discussed in detail. Furthermore, the broad spectrum of applications for thiolated chitosans in science and industry, ranging from their most advanced use in pharmaceutical and medical science over wastewater treatment to the impregnation of textiles, is addressed.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32567846 PMCID: PMC7805012 DOI: 10.1021/acs.biomac.0c00663
Source DB: PubMed Journal: Biomacromolecules ISSN: 1525-7797 Impact factor: 6.988
Figure 1Example of the synthesis of an S-protected thiolated chitosan derivative, displaying the initial structure of chitosan, an amidation with thioglycolic acid mediated by 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide (EDAC), and the protection/preactivation step with 6-mercaptonicotinamide (6-MNA; R = H) or the dimer form of this reagent, namely 6,6′-dithionicotinamide (R = 6-MNA).
Overview of Available Thiolated Chitosans with the Schematically Depicted Utilized Synthesis Method and Attached Thiol Ligand (CHIT = Chitosan Polymer
Where applicable limited to three references; for further references please contact the corresponding author.
Figure 2Properties gained by the covalent attachment of thiol groups to chitosan. (A) Adhesion of thiolated chitosans to biological surfaces such as mucins or keratins. (B) Cross-linking of thiolated chitosans due to disulfide formation, improving in situ gelling properties and mechanical stability. (C) Adjustable swelling behavior using different ligands and degrees of S-preactivation. (D) Controlled release of covalently bound active pharmaceutical ingredients (APIs) or prolonged API release out of cross-linked polymers. (E) Enhanced API permeation due to opened tight junctions caused by the interaction of thiolated chitosans with cysteine-bearing membrane receptors and enzymes. (F) Increased absorptive endocytosis of API-loaded thiolated chitosan carriers by disulfide formation with exofacial thiols of transmembrane proteins. (G) Inhibition of efflux pumps and enzymes due to the formation of disulfide bonds with thiolated chitosans. (H) Complexation of metal ions by sulfhydryl groups of thiolated chitosans. (I) Disulfide formation of thiolated chitosans, causing inactivation of reactive oxygen species. (J) Proven biocompatibility of thiolated chitosans in comparison to unmodified chitosan and customizable degradation rate of the thiolated polymer utilizing different ligands.
Figure 3Adhesion time of thiolated nanofiber mats to human buccal mucosa determined in human volunteers. Indicated values are mean (n = 3) ± SD. According to Samprasit et al.[128]
Figure 4Illustration of the tautomeric forms of chitosan–mercaptonicotinic acid and possible disulfide formation reactions of these forms. CHIT = chitosan polymer.
Figure 5Average compressive modulus of hydrogels composed of N-isopropylacrylamide and chitosan or chitosan–N-acetylcysteine calculated from the slope of the stress–strain curve in a range of 10–20% strain (toe region). NC = N-isopropylacrylamide-g-chitosan copolymer; TNC = thiol-modified N-isopropylacrylamide-g-chitosan with different amounts of free thiol groups (TNC50: 101.84 ± 18.35 μmol/g, TNC100: 141.91 ± 27.15 μmol/g, TNC200: 299.39 ± 8.11 μmol/g). Significantly higher moduli were observed for TNC100 as well as TNC200 compared to NC and TNC50 (p < 0.05). Indicated values are means (n = 3) ± SD. Reprinted with permission from ref (138). Copyright 2018 Elsevier.
Figure 6In vitro release profiles of BMP2-derived peptide P24 (P24) from chitosan–4-thio-butylamidine/β-glycerophosphate disodium/hydroxyapatite (CS-TBA/β-GP/HA) as well as from chitosan/β-glycerophosphate disodium/hydroxyapatite (CS/β-GP/HA) hydrogels. Indicated values are means (n = 4) ± SD. Reprinted with permission from ref (148). Copyright 2016 Elsevier.
Figure 7Concentration of curcumin (CUR) in New Zealand albino rabbit tears after ocular administration of CUR embedded in eye drops, nanostructured lipid carriers (NLCs), NLCs coated with chitosan (CH-NLC), or NLCs coated with chitosan–N-acetylcysteine (CS-NACH-NLC). Indicated values are means (n = 6) ± SD. Reprinted with permission from ref (143), licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Figure 8Potential mechanisms of thiolated chitosan drug carriers reacting with proteins displaying exofacial thiol groups. (a) A disulfide bond exchange reaction between a reactive thiol group at the cell surface and a disulfide bond of the vector takes place. (b) Again a disulfide bond exchange reaction occurs whereby this time a thiol group of the carrier attacks a disulfide bond of the protein. (c) Formation of a disulfide bridge between a thiol group of the vector and an exofacial thiol group of a protein. Metal ions or oxidizing agents can enhance this reaction. Each time a mixed disulfide complex emerges, it is internalized and subsequently reduced within the endosome or cytoplasm, resulting in release of the carrier. Reprinted with permission from ref (163). Copyright 2012 Elsevier.
Figure 9Concentration–time curve of paclitaxel (PTX) in rat plasma. PTX was orally administered via the reference market product Taxol, micelles based on N-octyl-O,N′-glycol chitosan (OGC-PTX), or micelles prepared with N-mercaptoacetyl-N′-octyl-O,N″-glycol chitosan (SH-OGC-PTX). Indicated values are means (n = 3) ± SD. Reprinted with permission from ref (80). Copyright 2018 Elsevier.
Figure 10Removal efficiencies of nanoparticles prepared with chitosan–Fe3O4 (CS-Fe3O4), N-(2-hydroxyl)propyl-3-trimethylammonium chitosan chloride–Fe3O4 (HTCC-Fe3O4), and N-(2-hydroxyl)propyl-3-trimethylammonium chitosan chloride–cysteine–Fe3O4 (Cyshtcc-Fe3O4). Reprinted with permission from ref (32). Copyright 2018 Elsevier.
Figure 11Antioxidative activity expressed as percentage amount of 1,1-diphenyl-2-picrylhydrazyl radical (DPPH) inhibition of different chitosan hydrogels, depending on the degree of chitosan thiolation as well as the concentration of chicoric acid (ChA) used for cross-linking and gelation of the thiolated chitosans. Thiolated chitosans used for hydrogel preparation displayed 212.5 μmol (TCS1-10), 372.5 μmol (TCS1-5), or 502.7 μmol (TCS2-5) of free thiol groups per gram of polymer. Indicated values are means (n = 3) ± SD. Statistical significance was calculated using one-way ANOVA (p < 0.05). Reprinted with permission from ref (99). Published by The Royal Society of Chemistry and licensed under a Creative Commons Attribution 3.0 Unported Licence (CC BY 3.0).
Overview of Various Thiolated Chitosans Displaying Biocompatibility within the Listed Studies
| derivative | utilized cytotoxicity tests | references | |
|---|---|---|---|
| (2-hydroxyethyl)ethylenediamine chitosan–thioglycolic acid | cell assay | MTT assay on Calu-3 and A549 cells | ( |
| chitosan–4-thiobutylamidine | cell assays | viability assay on human dermal fibroblasts utilizing Presto Blue | ( |
| cell count and morphology investigation of human dermal fibroblasts after staining with Hoechst and phalloidin conjugated to Alexa Fluor 488 dye | ( | ||
| effect of polymer gel formulations on ciliary beat frequency of human nasal epithelial cells | ( | ||
| Alamar Blue assay with human skin fibroblasts using hydrogel formulations | ( | ||
| direct contact assay on HeLa, Caco-2/TC7, and HT-29/MTX cells | ( | ||
| red blood cell lysis test | ( | ||
| BrdU-based enzyme-linked immunosorbent assay on L-929 mouse fibroblast cells | ( | ||
| MTT assay on L-929 mouse fibroblast cell | ( | ||
| in rats | polymer hydrogel injected into the spinal cord of male Wistar rats | ( | |
| chitosan–cysteine | cell assays | cell counting kit-8 assay on HaCaT and MCF-7 cells | ( |
| MTT assay on human stomach carcinoma epithelial cells | ( | ||
| MTT assay on human osteosarcoma and HEK 293 T cells | ( | ||
| live/dead assay on human osteosarcoma, HEK 293 T and MCF-7 cells | ( | ||
| in humans | nanofiber mats were applied on buccal mucosa | ( | |
| chitosan–lauric acid–thioglycolic acid | cell assay | MTT assay on human gingiva cells | ( |
| chitosan–mercaptoundecanoic acid | cell assays | MTT assay on human osteosarcoma and HEK 293 T cells | ( |
| live/dead assay on human osteosarcoma and HEK 293 T cells | ( | ||
| chitosan– | cell assay | LDH assay on human conjunctival cells | ( |
| in rabbits | polymer microspheres investigated in eyes of albino New Zealand rabbits | ( | |
| eye drops applied in albino New Zealand rabbits | ( | ||
| in humans | clinical investigations using eye drops | ( | |
| chitosan–thioglycolic acid | cell assays | MTT assay on bone-marrow-derived macrophages | ( |
| MTT assay on human corneal epithelium cells | ( | ||
| in rats | Draize skin irritation method with microneedle patches | ( | |
| glycol chitosan–glutathione | cell assay | MTT assay on CaCo-2 cells | ( |
| glycol chitosan– | cell assay | MTT assay on CaCo-2 cells | ( |
| hexanoyl glycol chitosan–mercaptopropionic acid | cell assays | MTT assay on HeLa cells and human lung fibroblasts | ( |
| direct contact test with human conjunctiva epithelial cells | ( | ||
| live/dead assay with human conjunctiva epithelial cell aggregates | ( | ||
| cell assays | LDH and XTT assay on Calu-3 cells | ( | |
| XTT assay on H1299 cells | ( | ||
| S-protected chitosan–EDTA–cysteine | cell assay | Resazurin assay on CaCo-2 cells | ( |
| S-protected chitosan– | cell assay | Resazurin assay on bladder mucosa | ( |
| S-protected glycol chitosan–glutathione | cell assay | MTT assay on CaCo-2 cells | ( |
| S-protected glycol
chitosan– | cell assay | MTT assay on CaCo-2 cells | ( |
| trimethyl-chitosan–cysteine | cell assay | XTT assay on HEK293T and MCF-7 as well as SKOV-3 cells | ( |
| trimethyl chitosan– | cell assay | MTT assay on HeLa cells | ( |
Overview of Dosage Forms Based on Thiolated Chitosans
| dosage form | active pharmaceutical ingredient | references |
|---|---|---|
| eye drops | chitosan– | ( |
| chitosan–cysteine | ( | |
| hydrogel | leuprolide | ( |
| liposomes | calcitonin | ( |
| docetaxel | ( | |
| micelles | paclitaxel | ( |
| microparticles | acyclovir | ( |
| nanoemulsion | curcumin | ( |
| nanoparticles | amoxicillin | ( |
| cherry extract delivery | ( | |
| docetaxel | ( | |
| fluorescein diacetate as model compound | ( | |
| insulin | ( | |
| low-molecular-weight heparin | ( | |
| Map4k4 siRNA | ( | |
| paromomycin | ( | |
| sitagliptin | ( | |
| TNF-α siRNA | ( | |
| polymer solution | Rhodamine-123 as model P-gp substrate | ( |
| polymer tablets | antide | ( |
| calcitonin | ( | |
| insulin | ( | |
| naproxen | ( | |
| Rhodamine-123 as model P-gp substrate | ( | |
| self-emulsifying drug delivery system | insulin | ( |
| nanoparticles | curcumin | ( |
| polymer solution | dexamethasone | ( |
| hydrogel containing proniosomes | duloxetine | ( |
| microparticles | insulin | ( |
| paliperidone | ( | |
| nanoparticles | bovine serum albumin as model compound for vaccination | ( |
| galantamine | ( | |
| insulin | ( | |
| leuprolide | ( | |
| pDNA encoding for green fluorescent protein | ( | |
| selegiline | ( | |
| theophylline | ( | |
| tizanidine | ( | |
| freeze-dried hydrogels | bovine serum albumin as model macromolecular compound | ( |
| insulin | ( | |
| nanofiber mats | ( | |
| α-mangostin | ( | |
| polymer films | calcium fluoride | ( |
| fluconazole | ( | |
| lignocaine | ( | |
| risedronate | ( | |
| polymer films containing nanoparticles | insulin | ( |
| polymer solution | pituitarity adenlyate cyclase-activating polypeptide | ( |
| polymer tablets | pituitarity adenlyate cyclase-activating polypeptide | ( |
| microparticles | tenofovir | ( |
| nanofibers | tenofovir | ( |
| nanoparticles | tenofovir | ( |
| polymer tablets | metronidazole | ( |
| microparticles | fluorescein diacetate as model compound | ( |
| nanoparticles | fluorescein diacetate as model compound | ( |
| gemcitabine | ( | |
| Nanoparticles | calcitonin | ( |
| polymer film | carvedilol | ( |
| microneedle patch | tacrolimus | ( |
| microcapsules | probiotic bacteria | ( |
| hydrogels | bendamustine | ( |
| curcumin | ( | |
| nanoparticles | 5-fluorouracil | ( |
| curcumin | ( | |
| meglumine antimoniate | ( | |
| pDNA encoding for green fluorescent protein | ( | |
| TNF-α siRNA | ( | |
| VEGF siRNA | ( | |
Overview of Application Forms of Thiolated Chitosans
| application form | function | references |
|---|---|---|
| cell chip | cell-mediated cytotoxicity assay, disease diagnosis, and anticancer drug assessments | ( |
| nanoparticles | intravascular optical imaging of high risk plaques | ( |
| long-time imaging of HeLa cells | ( | |
| theranostic agent for tumors | ( | |
| nanorods | photothermic agent | ( |
| superparamagnetic iron oxide nanoparticles | ( | |
| electrospun membranes | delivery of VEGF and PDGF for blood vessel regeneration | ( |
| electrospun membranes | delivery of QK peptide for blood vessel regeneration | ( |
| hydrogels | carrier for cell-specific bioactive extracellular matrices | ( |
| support of chondrocyte growth and matrix deposition to promote cartilage repair | ( | |
| thermosensitive cell carrier/scaffold for tissue regeneration | ( | |
| polyelectrolyte multilayers | redox-mediated fibronectin and fibroblast adhesion | ( |
| free-standing membranes or coatings of implants and tissue engineering scaffolds | ( | |
| scaffold | biomimetic scaffold for the controlled and sustained delivery of BMP-derived peptide P24 to promote osteogenesis and bone repair | ( |
| bandage | biodegradable bandage for the treatment of surgical site infections | ( |
| freeze-dried hydrogel | hemostatic dressing | ( |
| hydrogels | dressing for chronic wound management | ( |
| gel formulation to accelerate wound closure and promote angiogenic markers, alignment of collagen fibers, and blood vessel formation | ( | |
| polymer films | antibacterial additives for the plastic industry | ( |
| bacterial anti-adhesive coating | ( | |
| high-performance composite for functional devices or fuel cells | ( | |
| polymer solution | development of antimicrobial coatings | ( |
| polymer grafted textile | biocidal finishing agent in textile production | ( |
| 3D sponge | wastewater treatment of organic dye pollution and bacteria contamination | ( |
| chitosan beads | adsorption of precious metals | ( |
| magnetic composite | metal remediation under neutral conditions | ( |
| multilayer immunosensor | biocompatible and sensitive
immunosensor for detecting | ( |
| nanoceria | photo-inactivation of bacteria in hospital effluent | ( |
| polymer film | adsorption of Ni2+ from aqueous solutions | ( |
| polymer solutions | As3+/As5+ removal in groundwater | ( |
| selective and sensitive Hg2+ colorimetric sensor | ( | |
| creams | preventing the permeation of heavy metals ion into the skin to inhibit contact dermatitis | ( |
Diagnosis and Severity of Dry Eye Disease Symptoms of 18 Patients Pre and Post (3 Weeks) Treatment with One Eye Drop of Lacrimera in the Morning for 5 Daysa
| OSDI (subjective) | OGS (objective) | |||
|---|---|---|---|---|
| associated condition | pre | post | pre | post |
| granular dystrophy, corneal grafts | 62.5 | 31.3 | III | I |
| persistent epithelial defect, glaucoma | 55.6 | 41.7 | II | I |
| ocular cicatricial pemphigoid, persistent epithelial defect | 53.6 | 35.7 | III | II |
| glaucoma | 46.9 | 31.3 | II | I |
| lasik | 71.4 | 17.9 | IV | 0 |
| rheumatoid arthritis | 35.7 | 17.9 | II | I |
| epithelial defect, neurotrophic keratopathy | 25 | 12.5 | I | 0 |
| superior limbic keratitis | 22.7 | 11.4 | II | I |
| rheumatoid arthritis | 50 | 25 | III | I |
| dry eyes | 45.5 | 11.4 | III | 0 |
| ocular cicatricial pemphigoid, glaucoma, dry eyes | 55.6 | 41.7 | II | I |
| corneal graft, dry eyes | 46.9 | 31.3 | III | II |
| corneal decompensation | 37.5 | 25 | II | I |
| glaucoma | 46.9 | 15.6 | III | 0 |
| neurotrophic keratopathy | 41.7 | 21.8 | II | I |
OSDI = Ocular Surface Disease Index; OGS = Oxford Grading System. Adapted with permission from ref (195), distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Overview of In Vivo Studies with Drug Delivery Systems Comprising Thiolated Chitosans (TC; CS = Pristine Chitosan or Corresponding Mother Polymer)
| derivative | species | application form | application | results | references |
|---|---|---|---|---|---|
| chitosan–4-thiobutylamidine | mice | nanoparticles | intravenous delivery of 5-fluorouracil and curcumin | A sustained release over 72 h of curcumin and 5-fluorouracil was achieved by incorporating these APIs in TC nanoparticles. Furthermore, an 18.8-fold higher AUC was analyzed for 5-fluorouracil compared to the API solution, and for curcumin a 6.5-fold increased AUC was obtained. | ( |
| rats | microparticles | nasal insulin delivery | A bioavailability of 7% and a calculated absolute pharmacological efficacy of 5% were obtained for TC. CS displayed a bioavailability of 4% and a pharmacological efficacy of 0.7%. | ( | |
| oral acyclovir delivery | Mean residence time of TC microparticles was 17.9 h. CS particles showed only a mean residence time of 12.4 h. Furthermore, a 1.2-fold higher AUC was obtained for TC microparticles in relation to CS particles. | ( | |||
| polymer tablets | oral calcitonin delivery | Delivery system based on TC decreased the plasma calcium concentration to 91%, whereas control tablets based on CS had no impact on plasma calcium level. | ( | ||
| oral delivery of P-gp substrates | Tablets based on TC increased the AUC of Rhodamine-123 by 217% in comparison to buffer control and by 58% compared to CS. | ( | |||
| pigs | polymer tablets | buccal pituitary adenylate cyclase-activating polypeptide delivery | Delivery system based on TC led to a bioavailability of 1%, whereas no API was detected in plasma using CS. | ( | |
| oral antide delivery | For the administered solution, no API was analyzed in plasma. In contrast, for TC tablets, an absolute bioavailability of 1.1% was obtained. | ( | |||
| chitosan–cysteine | mice | hydrogel | curcumin-containing formulations were injected into the breast fat pad | For the hydrogel composed of TC-coated liposomes, no tumor recurrence was observed, whereas unmodified liposomes displayed a recurrence rate of 50%. | ( |
| chitosan–glutathione | rats | nanoparticles | oral docetaxel delivery | Oral bioavailability of the API was increased to 68.9% for TC nanoparticles compared to 6.5% for the commercially available reference. Furthermore, for TC nanoparticles, a drug release for 216 h was observed, whereas for the commercially available reference product, the release lasted only for 24 h. | ( |
| chitosan–mercaptonicotinic acid | mice | nanoparticles | oral insulin delivery | The AUC after oral administration of TC nanoparticles was 4-fold improved compared to that of CS nanoparticles. | ( |
| nanoparticles | intramuscular delivery of pDNA encoding for green fluorescent protein | Gene expression persisted up to 60 days. | ( | ||
| rats | polymer tablets | oral insulin delivery | For tablets based on TC, a 4.8-fold higher AUC was observed in comparison to those based on CS. | ( | |
| chitosan–mercaptopropionic acid | rats | nanoparticles | oral insulin delivery | An increased insulin concentration and a decreased glucose level were analyzed for streptozotocin-induced diabetic rats. | ( |
| chitosan– | rats | nanoparticles | nasal insulin delivery | Intranasal administration of API-loaded nanoparticles based on TC enhanced the relative bioavailability of the API (12%) compared with CS nanoparticles (7%) and control insulin solution (1%). | ( |
| rabbits | nanoparticles | ocular curcumin delivery | For TC-coated nanoparticles, the significantly highest ocular retention was observed by fluorescence imaging, and a 29.9-fold increased AUC was obtained compared to that with curcumin eye drops. Uncoated nanoparticles displayed a 6.0-fold higher AUC, and for CS-coated nanoparticles a 12.3-fold increased AUC was detected. | ( | |
| humans | nanofiber mats | local oral delivery of | API-loaded nanofiber mats
based on TC achieved a ≥70% reduction
in | ( | |
| chitosan–thioglycolic acid | mice | nanoparticles | nasal theophylline delivery | Theophylline administered via TC nanoparticles more strongly attenuated pulmonary inflammation and epithelial damage as well as goblet cell hyperplasia and resulted in a lower amount of infiltrated inflammatory cells compared to API delivery by CS nanoparticles. | ( |
| nasal vaccination with bovine serum albumin (proof of concept) | High levels of IgG, IgG1, and IgG2a antibodies were found within the animals, demonstrating the potential of TC-based carriers for nanovaccines. | ( | |||
| nasal delivery of selegiline | Animals treated with a system based on TC showed a significantly reduced immobility time, increased sucrose water intake, and higher locomotor activity compared to the group receiving a formulation with unmodified polymer. | ( | |||
| intranasal delivery of plasmid DNA encoding for green fluorescent protein | Cross-linked TC/pDNA nanoparticles displayed a significantly higher transfection efficacy (47%) after 14 days in comparison to particles based on CS (21%). | ( | |||
| rats | hydrogels | oral leuprolide delivery | Gel formulation based on TC and CS led to an absolute bioavailability of 283% and 43%, respectively. | ( | |
| nanoparticles | oral low-molecular-weight heparin delivery | Compared with nanoparticles based on CS, the anticoagulant effect was significantly longer (maximal activated partial thromboplastin time was 2-fold increased) for nanoparticles based on TC. | ( | ||
| oral docetaxel delivery | Oral bioavailability was 7.5-fold improved in comparison to DTX suspension. | ( | |||
| oral sitagliptin delivery | A 4.7-fold increased efficacy in lowering plasma glucose concentration was achieved for TC nanoparticles compared to the API solution. | ( | |||
| nasal leuprolide delivery | An absolute bioavailability of 2.6%, 4.3%, or 18.5% was observed by administering the API in solution or via nanoparticles based on CS or TC, respectively. | ( | |||
| pulmonary calcitonin delivery | For calcitonin-loaded nanoparticles based on TC, the hypocalcemic effect lasted for 24 h and a pharmacological availability of 40% was analyzed, whereas for CS nanoparticles, a hypocalcemic effect of 12 h and pharmacological availability of 27% were obtained. | ( | |||
| intravesical delivery | More than 50% of nanoparticles based on TC remained in the bladder after 6 h, resulting in a 4-fold higher bioadhesion compared to unmodified CS nanoparticles. | ( | |||
| self-emulsifying drug delivery system | oral insulin delivery | TC formulation displayed a 3.3-fold higher AUC compared to oral insulin solution | ( | ||
| chitosan–thioglycolic acid–6-mercaptonicotinamide | rats | liposomes | oral salmon calcitonin delivery | Liposomes coated with TC and S-preactivated TC achieved 5.7- and 8.2-fold improved decreases in blood calcium level, respectively, in comparison to the API administered in solution. | ( |
| polymer tablets | oral antide delivery | An absolute bioavailability of 0.03% was observed for CS tablets, which could be increased to 1.4% using TC tablets. | ( | ||
| dimethyl ethyl chitosan–mercaptopropionic acid | rabbit | polymer solution | ocular dexamethasone delivery | CS-API solution showed a 3.4-fold higher AUC in comparison to the API solution without chitosan. For the TC-API solution, however, a 5.7-fold higher AUC was found. | ( |
| galactosylated trimethyl-chitosan–cysteine | mice | nanoparticles | oral delivery of Map4k4 siRNA | Daily oral administration of galactolsylated TC nanoparticles containing siMap4k4 significantly improved dextrane sulfate sodium-induced ulcerative colitis body weight loss, colon length shortening, and increase of myeloperoxidase activity. | ( |
| hexanoic acid, 6-[(mercapto-1-oxopropyl)amino]chitosan | mice | nanoparticles | oral delivery of TNF-α siRNA | TC particles showed high accumulation at the arthritic joint sites in collagen-induced arthritis mice, significantly inhibiting inflammation and bone erosion comparable to methotrexate (5 mg/kg). | ( |
| intravenous administration of VEGF siRNA | A 34.4% decreased VEGF expression in extracted tumor tissue was analyzed for TC nanoparticles in reference to the control. Moreover, a synergistic effect was obtained by administering TC nanoparticles together with bevacizumab, as thereby VEGF expression was reduced by 43.5%. | ( | |||
| mannosylated trimethyl-chitosan–cysteine | mice | nanoparticles | oral delivery of TNF-α siRNA | Orally delivered TC nanoparticles inhibited TNF-α production in macrophages, protecting mice with acute hepatic injury from inflammation-induced liver damage and lethality. | ( |
| rats | micelles | oral paclitaxel delivery | TC micelles increased the bioavailability of paclitaxel to 78%, being 3.8-fold higher compared to the marketed reference product and 1.4-fold higher in relation to micelles based on CS. | ( | |
| thiomalylchitosan | rats | nanoparticles | oral insulin delivery | For insulin-loaded TC nanoparticles, a 35% reduced blood glucose level was observed, whereas for CS nanoparticles blood glucose level decreased by 17%. | ( |
| trimethyl-chitosan–cysteine | mice | nanoparticles | intramuscular delivery of pDNA encoding for green fluorescent protein | Transfection with TC achieved a 2.3-fold and 4.1-fold higher efficiency than CS and Lipofectamine2000, respectively. | ( |
Figure 12Docetaxel plasma concentration in rats after intravenous injection of the market formulation Taxotere (red ■), oral administration of Taxotere (green ▲), and oral administration of docetaxel-loaded nanoparticles coated with chitosan–glutathione (DTX-loaded NP, blue ◆). Indicated values are means (n = 5) ± SD. Reprinted with permission from ref (63). Copyright 2013 Saremi et al., distributed under the Creative Commons Attribution License (CC BY 3.0).
Figure 13Cell viability of MDA-MB-231 line treated with GNRs. Photothermal efficiency (η) of GNRs covered with different polymers. Chi–SH-GNR = chitosan-coated GNRs; Alg-Chi-SH-GNR = chitosan-coated GNRs covered with alginate; PVA-Chi-SH-GNR = chitosan-coated GNRs covered with poly(vinyl alcohol). Reprinted with permissions from ref (237). Copyright 2017 Elsevier.
Figure 14Illustrative comparison of the mechanical characteristics of an unmodified chitosan hydrogel and a thiolated chitosan hydrogel intended for use in tissue engineering.
Figure 15In vivo analysis of wound healing ability of bandages in mice wounded by sterilized needles near the hind limb. Graph showing speed of wound closure in terms of reduction in wound size after application of bandages. CS-Alg-ZnO = chitosan alginate zinc oxide nanoparticles; TCS-Alg-ZnO = thiolated alginate zinc oxide nanoparticles. Reprinted with permission from ref (71). Copyright 2019 Arshad et al., distributed under the terms of the Creative Commons Attribution License (CC BY 4.0).
Figure 16Evaluation of anti-adhesive properties of films based on gold (Au), Chitosan (Ch_Buffer), and chitosan–N-acetylcysteine (Ch_NAC4). (A) S. aureus adhesion on Au, Ch_Buffer, and Ch_NAC4 films after 2 h incubation in growth medium (white bars) and 4 h re-incubation on fresh growth medium after the 2 h pre-incubation period (black bars). (B) S. aureus adhesion on Au, Ch_Buffer, and Ch_NAC4 after 2 h incubation in phosphate-buffered saline (PBS) or PBS supplemented with 1% human plasma. (C) Mass of proteins from 1% (v/v) human plasma adsorbed on Au, Ch_Buffer, and Ch_NAC4 surfaces. (D) Effect of Au, chitosan, and thiolated chitosan on S. aureus total biofilm biomass formation. Data represented as means (n = 3) ± SD. Reprinted with permission from ref (245), licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Figure 17Schematic depiction of grafting chitosan–N-acetylcysteine onto wool fibers.
Adsorption Capacities of Thiolated Chitosans Evaluated for Heavy Metal Removal
| species | adsorption (milligrams of heavy metal ion per gram polymer) | removal efficiency (%) | commentary | references |
|---|---|---|---|---|
| As3+ | 15.0–17.08 | 85.4 | Thiolated chitosan (amine and hydroxyl groups were substituted with −SH groups using thiourea and microwave irradiation) showed high adsorption ability for As3+ and As5+ at different pH ranges. Arsenic concentrations were reduced below the limit determined by the WHO for drinking water. Moreover, thiolated chitosan also efficiently adsorbed As5+ and As3+ in solutions with high concentrations of further ions. | ( |
| As5+ | 15.4–17.70 | 87.0 | ||
| Pd2+ | 175.4 | 83.58–99.08 | Adsorption and desorption efficiencies for Pd2+ comparable to those of commercially available resins like Lewatit TP214 were achieved using chitosan 3-amino-1,2,4-triazole-5-thiol as adsorbent. | ( |
| As5+ | 66.27 | 70–80 | Maximum
adsorption
capacity of | ( |
| As3+ | 67.69 | 60–70 | ||
| Hg2+ | 28.00 | 70–90 | ||
| Cu2+ | 33.99 | 90–100 | ||
| Zn2+ | 13.63 | 90 | ||
| Cd2+ | 16.34 | 90 | ||
| Pb2+ | 235.63 | 90–100 | ||
| Au3+ | 198.5 | 80 | The hydrogel based on chitosan–2,5-dimercapto-1,3,4-thiodiazole was efficient in removing Au3+, Pd2+, and Pt4+ from dilute solutions. Sorption studies revealed a considerable capacity for Au3+ ions, which might be useful in the removal of gold from ores. | ( |
| Pd2+ | 17.0 | 100 | ||
| Pt4+ | 15.3 | >80 | ||
| Ni2+ | 0.131 (mole of metal ion per mole polymer unit) | 83 | Chitosan-glutathione displayed a 40% higher adsorption capacity for Ni2+ ions from aqueous solution compared to the unmodified polymer. | ( |
| Cu2+ | 208–238 | n.d. | ( | |
| Hg2+ | 556–588 | n.d. | ||
Publication displays tables summarizing adsorption data of the corresponding pollutant published by other research groups.
Figure 18Schematic illustration of contact dermatitis prevention by cosmetics containing chitosan–glutathione.